Top Industry Leaders in the Mitochondrial Myopathy Diagnosis & Treatment Market
Latest Mitochondrial Myopathy Diagnosis & Treatment Companies Update:
Genea Biosciences Developed the MitoCarta™ Next-Generation Sequencing panel for comprehensive analysis of mitochondrial DNA mutations associated with various myopathies.Collaborated with research institutions to identify novel genetic markers for improved diagnosis and prediction of disease progression.
Sophia Genetics Expanded their AI-powered genetic analysis platform to include comprehensive interpretation of mitochondrial disease mutations. Partnered with hospitals and diagnostic centers to offer rapid and accurate genetic testing for mitochondrial myopathies.
Biomarin Pharmaceutical Received EU marketing authorization for Vimizim® (elapravir), a therapy aimed at improving mitochondrial protein synthesis in specific mitochondrial myopathies. Conducted clinical trials for other pipeline candidates targeting different causes of mitochondrial dysfunction.
Mitochondrial Therapeutics Developed MTI-001, a small molecule drug candidate undergoing Phase 2 clinical trials for the treatment of Leber's hereditary optic neuropathy, a common form of mitochondrial myopathy. Collaborating with academic institutions to advance research on other potential therapeutic targets for mitochondrial diseases.
List of Mitochondrial Myopathy Diagnosis & Treatment Key companies in the market
- AbbVie Inc.
- Centogene AG
- GeneDx
- Ixchel Pharma
- Khondrion BV
- Mitobridge
- NeuroVive Pharmaceutical AB
- Reata Pharmaceuticals Inc.
- Stealth Biotherapeutics